At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
MK-7162 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating MK-7162 and Pembrolizumab for Solid Neoplasms. Completed, enrolled 33 participants across 6 sites in 4 countries.
Detailed Summary
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Neoplasms
CountriesCanada, Israel, South Korea, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2017
Primary CompletionOct 2020
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartDec 6, 2017
Primary CompletionOct 19, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.6 years ago
Interventions
MK-7162drug
oral tablets
Pembrolizumabbiological
IV infusion